Lv11
90 积分 2026-01-03 加入
Blinatumomab: A historical perspective
5小时前
已完结
AB1034 CHARACTERIZATION OF RO7507062, A CD19-TARGETING T-CELL BISPECIFIC ANTIBODY (CD19TCB), AND DESIGN OF A PHASE 1 TRIAL IN SYSTEMIC LUPUS ERYTHEMATOSUS
17天前
已完结
T-cell engaging antibodies for B-cell lymphomas
17天前
已关闭
T-cell engaging antibodies for B-cell lymphomas
18天前
已关闭
Blinatumomab: A historical perspective
19天前
已完结
Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens
2个月前
已完结
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells
5个月前
已完结
Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1
5个月前
已完结
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
5个月前
已完结
ZAP327 signaling domain–driven chimeric antigen receptor generates robust and long-term antitumor immunity in mouse models
5个月前
已完结
皖公网安备34019202002308
